In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Julianne B RiggsDivision of Rheumatology, Rosalind Russell and Ephraim P. Engleman Arthritis Research Center, Department of Medicine, University of California, San Francisco, California 94143.
Alexander J RitterDivision of Rheumatology, Rosalind Russell and Ephraim P. Engleman Arthritis Research Center, Department of Medicine, University of California, San Francisco, California 94143.
François X P BourassaJoseph Henry Laboratories of Physics, Princeton University, Princeton, NJ 08544.ORCID 0000-0002-2757-5870 Alexander R MeyerDepartment of Pharmaceutical Sciences, 1007 E. Huron Street, University of Michigan, Ann Arbor, Michigan 48104.ORCID 0000-0003-4453-9561 Erika Kay-TsumagariDepartment of Pharmaceutical Sciences, 1007 E. Huron Street, University of Michigan, Ann Arbor, Michigan 48104.ORCID 0009-0002-0787-2074 Wei-Yun WholeyDepartment of Pharmaceutical Sciences, 1007 E. Huron Street, University of Michigan, Ann Arbor, Michigan 48104.ORCID 0000-0002-1235-6288 Jeremy LibangDivision of Rheumatology, Rosalind Russell and Ephraim P. Engleman Arthritis Research Center, Department of Medicine, University of California, San Francisco, California 94143.
James L MuellerDivision of Rheumatology, Rosalind Russell and Ephraim P. Engleman Arthritis Research Center, Department of Medicine, University of California, San Francisco, California 94143.
Wen LuDivision of Rheumatology, Rosalind Russell and Ephraim P. Engleman Arthritis Research Center, Department of Medicine, University of California, San Francisco, California 94143.
Wei ChengDepartment of Pharmaceutical Sciences, 1007 E. Huron Street, University of Michigan, Ann Arbor, Michigan 48104.ORCID 0000-0003-0332-1566 Julie ZikhermanDivision of Rheumatology, Rosalind Russell and Ephraim P. Engleman Arthritis Research Center, Department of Medicine, University of California, San Francisco, California 94143.ORCID 0000-0002-0873-192X Funding
MOLECULAR AND CELLULAR IMMUNOLOGYT32AI007334 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CYSTER, JASON G · 1988 to 2023
$11.0MMechanisms of B Cell Responses to Particulate AntigensR01AI155653 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHENG, WEI, ZIKHERMAN, JULIE · 2021 to 2025
$3.6MRegulation of CD4 T cell tolerance by the NR4A family of nuclear receptorsR01AI165706 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JULIE ZIKHERMAN · 2022 to 2026
$3.0MCellular Biotechnology Training Program (CBTP) - Years 31-35T32GM145304 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Guizhi Zhu · 2022 to 2026
$2.6MNuclear Receptors in B Cell Tolerance and Humoral Immune ResponsesR01AI148487 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZIKHERMAN, JULIE · 2020 to 2024
$2.0MThe cell and molecular mechanisms underlying CD28 costimulationR01AI114575 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZIKHERMAN, JULIE · 2024 to 2025
$795kNIAID NIH HHS R01 AI114575NIAID NIH HHS R01 AI148487NIAID NIH HHS R01 AI155653NIAID NIH HHS R01 AI165706NIAID NIH HHS T32 AI007334NIGMS NIH HHS T32 GM145304
6 · The paper itselfAbstract
How B cells discriminate self from foreign antigens remains a central question, given inherent autoreactivity of the mature B cell receptor (BCR) repertoire. Soluble antigen (sAg) induces tolerance, whereas patterned antigen display on virus-like particles (pAg) triggers robust B cell responses that can proceed without T cell help. Here, we show how this divergence arises early in BCR signaling. Unlike sAg, pAg can bypass a Lyn-dependent negative feedback loop to trigger digital signaling, such that ultra-low concentrations of pAg produce strong and sustained Ca
Indexed as
anergyB cell receptor (BCR) signalingB cell toleranceinhibitory co-receptorsITIMsMycNFATNF-κBvirus-like particlevirus-like structure
Identifiers
PMID42079227
PMCPMC13131645
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390